Given its anti-angiogenic activity, lenalidomide may have a role in the treatment of POEMS (Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder and Skin changes) syndrome. This prospective, open-label, pilot study evaluated the combination of lenalidomide + dexamethasone (RD) in 18 POEMS syndrome patients (13 pretreated, 5 newly-diagnosed but ineligible for high-dose therapy). Treatment consisted of six cycles of lenalidomide (25 mg/day for 21 days followed by 7 days rest) plus dexamethasone (40 mg/once a week). Patients responding after six cycles continued treatment until progression or unbearable toxicity. The primary endpoint was the proportion of patients with either neurological or clinical improvement. The RD combination was considered as deserving further evaluation if 9 of the first 15 patients responded. Ten responses were observed among the first 15 enrolled patients, meeting the primary endpoint. Fifteen of 18 patients (83%) completed six RD cycles: 13 (72%) patients responded and nine had both clinical and neurological improvement. Among the 15 patients who completed the six RD cycles, four were still on treatment after a 25-month follow-up. At 39 months of follow-up, all patients were alive with a 3-year progression-free survival of 59%. No patient discontinued RD for toxicity. Overall, the RD regimen showed a high incidence of prolonged symptoms improvement and was well tolerated in most POEMS patients.
POEMS syndrome is a rare, disabling disease defined by peripheral neuropathy (P), organomegaly (O), endocrinopathy (E), monoclonal plasma cell disorder (M) and skin changes (S), even if the diagnosis does not require that all these symptoms are present; furthermore, many others clinical signs are not included, such as sclerotic bone lesions, papilloedema, oedema ascites and effusions, pulmonary hypertension, Castleman disease, thrombocytosis and erythrocytosis, and increased levels of serum vascular endothelial growth factor (VEGF) (Bardwick et al, 1980) . This condition is often associated with the up-regulation of some cytokines, especially VEGF (Nobile-Orazio et al, 2009; Dispenzieri, 2015) . Although the course of the disease is often chronic, POEMS syndrome is potentially fatal and is associated with serious complications and worsened quality of life.
There is no standard therapy for POEMS syndrome. Curative radiotherapy is the recommended treatment for localized disease without bone marrow involvement and <3 skeletal lesions at X-ray evaluation (Humeniuk et al, 2013) . In patients with disseminated disease, systemic treatment is recommended (Dispenzieri, 2015) . Treatments for POEMS are based on the results of anecdotal reports due to the lack of randomized clinical trials, and therapy recommendations are often borrowed from other plasma cell disorders, such as multiple myeloma and amyloidosis (Li et al, 2011; D'Souza et al, 2012) . However, therapies used in immune-mediated neuropathies (plasmapheresis, intravenous immunoglobulin) appear ineffective. Corticosteroids can attenuate the symptoms for some time, without slowing disease progression (Dispenzieri, 2015) . Haematopoietic stem cell transplantation (HSCT) is considered the preferred initial therapy for young patients, although relapses have been reported (D'Souza et al, 2012) .
Given that most POEMS patients' present increased serum VEGF levels, therapy with anti-VEGF factors represents an appealing strategy. However, treatment with bevacizumab gave ambiguous results with fatal events (Sekiguchi et al, 2013) . Thalidomide + dexamethasone has been recently compared with dexamethasone alone: patients on thalidomide showed a reduction of VEGF serum level, but also worsened tolerability (Misawa et al, 2016) . Neurotoxicity makes thalidomide unsuitable for POEMS patients, due to pre-existing severe neuropathy (Sinisalo et al, 2004; Kim et al, 2006; Kuwabara et al, 2008) . On the other hand, bortezomib, alone or combined with chemotherapy/HSCT, was associated with clinical improvement without worsened neuropathy (Briani et al, 2013; He et al, 2017) .
Lenalidomide is a thalidomide-analogue that is effective in patients with pre-treated or newly-diagnosed multiple myeloma without neurotoxicity (Stankowski-Drengler et al, 2010) . The anti-angiogenic properties of lenalidomidewhich blocks the secretion of several cytokines, including VEGF -and its excellent tolerability make this therapy worth consideration for patients with POEMS syndrome.
We performed, for the first time to our knowledge, a prospective evaluation of the efficacy and tolerability of lenalidomide combined with dexamethasone (RD) in patients with POEMS syndrome not responsive to, relapsing after or ineligible for, HSCT.
Patients and methods

Patients
Eighteen adult (≥18 years) patients with POEMS syndrome, either pre-treated (n = 13) or treatment-na€ ıve (n = 5), were enrolled at two Italian Centres from October 2009 to October 2014. The diagnosis of POEMS was made according to Dispenzieri (2015) . Other inclusion criteria were: (i) life expectancy ≥6 months; (ii) ability to comply with the protocol requirements; (iii) females of child-bearing potential and males had to use multiple contraception methods; (iv) normal neutrophil (>1Á5 9 10 9 /l and platelet (>75 9 10 9 /l) counts, creatinine (≥20 ml/min), bilirubin [<1Á5 
Procedures
All patients received monthly cycles of the RD combination [lenalidomide 25 mg/day orally for 21 days (days 1-21) and dexamethasone orally 40 mg weekly]. RD combination was administrated until progression of disease (PD) or unbearable toxicity. Oral antithrombotic prophylaxis with acetylsalicylic acid 100 mg/day (or low molecular weight heparin in intolerant patients) was administered during RD treatment. Prophylactic cotrimoxazole 800 mg bid was given for two days/week. No prophylactic antiviral treatment was prescribed.
Assessments
Clinical response was evaluated using a specially prepared 'Clinical Response Evaluation Scale' (CRES) (Supplemental Data), which grades ten POEMS features (for each feature, a score ranging from 0 -i.e. normal -to 2 points is given, with a total maximum score of 20). The CRES scale includes several variables to evaluate most signs of POEMS. In more detail, we carried routine laboratory tests (blood count, total proteins, serum immunofixation, hormone blood panel); organomegaly, adenopathies and ascites were assessed by clinical examination and abdominal ultrasound. Lung function was evaluated by spirometry and chest Xray. Skin alterations were assessed clinically. Bone lesions were investigated by X-ray and -in some cases -positron emission tomography, which enabled the response to treatment to be evaluated. Measurement of serum VEGF levels was also performed by enzyme-linked immunosorbent assay (ELISA).
Neurological assessment was performed by the 'Overall Neuropathy Limitation scale' (ONLS), which evaluates evaluating the disability caused by neuropathy (Graham & Hughes, 2006 ) (Data S1). Haematological response was evaluated according to the International Myeloma Working Group (IMWG) criteria (Rajkumar et al, 2011) .
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During the first six cycles of therapy, patients were assessed every 4 weeks to monitor toxicity, and every 2 months to evaluate clinical, neurological and haematological response. After six cycles, a complete evaluation of both clinical and neurological response was performed and, in responding patients, every 3-6 months thereafter until therapy discontinuation.
Due to the explorative nature of this study, all data were analysed only by descriptive statistics. Progression-free survival (PFS; time from treatment initiation to documented progression, death of any cause or loss to follow-up, whichever occurred first) and overall survival (OS; time from time from treatment initiation to death of any cause or loss to follow-up, whichever occurred first) were evaluated by the Kaplan-Meier method. Clinical response was defined as an improvement in CRES of ≥3 points or ≥1 point in the ONLS after 6 cycles. Long-term evaluations were also performed. All analyses were performed using Stata v.13 (Stata Corp., College Station, TX: USA).
Results
Patients
In total, 18 patients (14 males; median age 60 years, range 44-76) were evaluated (Table I) . Thirteen patients had been previously treated for POEMS syndrome. Prior treatments were mostly steroids, alkylating agents and HSCT. Five patients were newly diagnosed and were not eligible for HSCT due to advanced age (n = 2), severe concomitant conditions (n = 2) and severe secondary pulmonary hypertension (n = 1).
All 18 patients had a sensory motor neuropathy (ONLS score 4Á5; range 1-8). Serum VEGF levels were increased (>1000 pg/ml) in 17 patients (94Á4%; median concentration 2339 pg/ml, range 687-13Á856). Osteosclerotic bone lesions were reported in 12 patients (67%), while two (11%) patients had Castleman disease. Skin changes were observed in 16 patients (89%), hepatosplenomegaly in 14 (78%), pleural A. Nozza et al effusion, ascites or peripheral oedema in six (33%), and endocrine alterations in 16 (89%).
Efficacy at 6 months
One patient voluntarily suspended treatment during the first cycle, one was not compliant to study treatment and was lost to follow-up after one cycle, and one patient did not respond after 4 cycles. Nonetheless, all 18 patients were considered for the analysis of efficacy (Figs 1 and 2) .
Of the 18 patients, 13 (72%) responded to RD. Nine patients experienced both clinical and neurological improvement, 3 only clinical and 1 only neurological. Twelve of the 18 (67%) patients showed a ≥3-point improvement in CRES score compared with baseline (median score: 10 at entry; 6 at six months; P < 0Á001). Ten of the 18 (56%) patients improved their ONLS score by ≥1 point (median score: 4Á5 at entry; 4Á0 at six months; P = 0Á015). After six months of treatment, all other clinical parameters improved (Table II) . A haematological complete response (CR) with Thirteen patients (66Á7%) had a reduction of serum VEGF, compared with pre-treatment levels [entry: 2339 pg/ ml (range: 687-10512); 6 months: 873 pg/ml (range: 300-3579), P = 0Á004], and in six patients the value normalized. VEGF levels remained within the normal range in one patient; in another patient, increased of VEGF levels at 6 months were associated with worsened ONLS.
Long-term assessments
All of the 15 patients who completed the 6 RD cycles continued the treatment for a median of 25 months (range 10-58), with periodical assessment. CRES was available for 14 patients at 12 months and for 11 patients at 24 months (Fig 1) . After 12 months, 5/14 patients (36%) had further improvement in CRES score (range: + 1 to À6 points), with stability in one patient. Efficacy, as assessed by CRES, was sustained up to 24 months (Fig 1) .
After 12 months, 4/13 patients (31%) had further improvement in ONLS, with neurological stability in eight patients (Fig 2) . One patient worsened.
Serum VEGF levels remained reduced after 12 months (median value: 796 pg/ml, range 272-2649; P = 0Á009) and 24 months in responding patients (798 pg/ml, range 328-1976; P = 0Á008) compared with baseline (Fig 3) .
Survival and outcomes
With a median follow-up of 39 months, no patient died and six progressed. PFS at 3 years was 59% and overall survival (OS) was 100% (Fig 4) . At the end of the follow-up, six patients were still on therapy. Five patients, all of whom were pre-treated, showed PD and suspended treatment (after 10, 21, 29, 30 and 35 months. Treatment was suspended in two patients (after 25 and 32 months, respectively) due to a stabilized improvement of disease; one of these patients relapsed 20 months after RD interruption. None of the patients developed secondary tumours during the follow-up. 
Safety
Treatment with RD was well tolerated during the 6-month therapy, and no severe adverse events (AEs) or treatment interruption due to AEs occurred. Four patients developed haematological toxicity graded II-III (2 neutropenia, thrombocytopenia and anaemia) without reducing lenalidomide dose. One patient developed parotid gland hypertrophy, which persisted throughout the entire treatment period and after suspension of therapy 2 years later. One patient developed eyelid oedema during the first cycle, and he voluntary suspended treatment. One patient developed blood hypertension related to steroid therapy. No patients developed thrombosis. None of the 15 patients who completed the 6 RD cycles interrupted treatment for toxicity. Lenalidomide was reduced for haematological toxicity (grade II-III; 1 patients to 20 mg/ day, 3 to 15 mg/day and 2 to 10 mg/day) in six patients, while dexamethasone was reduced in all patients and subsequently suspended in 30% of them.
Discussion
To date, evidence in POEMS has been collected only in retrospective studies, often with small sample sizes; just one randomized controlled study has been recently completed (Misawa et al, 2016) .
The combination of lenalidomide, which blocks the increased secretion of interleukin 6 (IL6), tumour necrosis factor (TNF)-alpha and VEGF, with high-dose dexamethasone could be effective in POEMS, without evidence of neurotoxicity (Dalla Torre et al, 2016) . When we planned this prospective protocol, no data were available except for the case of a patient treated with lenalidomide and high-dose dexamethasone . Afterwards, similar findings were reported in other case reports or small series, despite a short follow-up (Suyanı et al, 2011; Vannata et al, 2012; Royer et al, 2013; Cai et al, 2015) . In a pooled analysis of 51 newly diagnosed or relapsed-refractory POEMS patients, lenalidomide was associated with a haematological response rate of 95Á3%, neurological response rate of 92% and 1-year PFS of 93Á9% (Zagouri et al, 2014) .
Our study prospectively evaluated, for the first time to our knowledge, the efficacy and safety of lenalidomide in patients with POEMS relapse or in patients not eligible for high-dose therapy (due to age or medical condition). Given that standard response criteria for multiple myeloma and amyloidosis are often inapplicable in POEMS (Dispenzieri, 2007 (Dispenzieri, , 2011 , we assessed efficacy by applying both a pre-planned scalealthough not validated -assessing patients' clinical features (CRES) and a neurological scale (ONLS). However, the heterogeneity of the prior treatments and the different times from disease diagnosis make the data less interpretable.
In our study, after six months, 83% of patients had improved clinical or neurological conditions or both. Moreover, 80% showed a relevant clinical response, with ≥3-point improvement in CRES. RD treatment led to a clinically relevant improvement after only 6 months of therapy, particularly in terms of regression of oedema, ascites and adenopathies, and amelioration of skin lesions. Ten patients (56%) improved by ≥1 point in the ONLS scale, which assessed patient disability. Two wheelchair-bound patients became able to walk with crutches after few months of treatment. Clinical and neurological improvement correlated with a reduction of VEGF serum levels, observed as early as after the first course of therapy.
The effectiveness of RD was confirmed over long-term follow-up (33 months), with 12/18 patients (66%) showing a persistent remission or stable improvement. Among six patients who suspended the treatment due to stabilized improvement, only one relapsed 20 months after lenalidomide interruption. Five pre-treated POEMS patients reported clinical and neurological progression of the disease and suspended RD treatment. No patient discontinued treatment due to AEs although lenalidomide dose was reduced in six patients, mainly for haematological toxicity grade II-III, suggesting that this therapy has a sustainable toxicity profile over the long-term.
Conclusions and perspectives
Our prospective study showed the efficacy of RD combination on clinical and neurological impairment and neurological disability in the majority of patients with POEMS syndrome who were unsuitable for, unresponsive to, or relapsed after other therapies, including HSCT. Improvement was observed after few cycles of therapy, and persisted in the majority of patients for more than 24 months, without major toxicity.
Given these results and the rapid effect of this therapy, we think that the RD combination may be also considered as initial short-term therapy (4-6 months) in young patients with POEMS syndrome eligible for high-dose therapy and HSCT, and in patients whose clinical conditions could exclude this treatment, in order to induce a rapid improvement, potentially allowing transplantation. In addition, lenalidomide might represent a suitable long-term therapy in patients who are not candidates for or who relapsed after high-dose therapy. Further investigations in phase II and III trials are required to better assess our findings.
